文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗联合瑞拉利单抗治疗晚期黑色素瘤的三年总生存:RELATIVITY-047研究

Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
PubMed 文献 · J Clin Oncol · 2024-12-13

RELATIVITY-047试验更新分析显示,中位随访33.8个月时,纳武利尤单抗联合瑞拉利单抗较纳武利尤单抗单药在晚期黑色素瘤患者中持续显示无进展生存获益(HR 0.79),总生存HR为0.80(95%CI 0.66-0.99),未发现新的安全性信号。

要点

  • 中位随访33.8个月,联合组中位无进展生存10.2个月 vs 单药组4.6个月(HR 0.79)。
  • 联合组中位总生存51.0个月 vs 单药组34.1个月(HR 0.80,95%CI 0.66-0.99)。
  • 联合组客观缓解率43.7% vs 单药组33.7%,未发现新的安全性信号。

核心结论

  • 在3年随访时,纳武利尤单抗联合瑞拉利单抗较纳武利尤单抗在晚期黑色素瘤患者中的获益持续存在,总生存HR的95%CI上限现已<1。

研究设计与样本

  • RELATIVITY-047试验(ClinicalTrials.gov标识符:NCT03470922)的更新描述性疗效和安全性分析,中位随访33.8个月。

主要发现

  • 联合组中位无进展生存10.2个月(95%CI 6.5-15.4)vs 单药组4.6个月(95%CI 3.5-6.5),HR 0.79(95%CI 0.66-0.95)。
  • 联合组中位总生存51.0个月(95%CI 34.0-未达到)vs 单药组34.1个月(95%CI 25.2-44.7),HR 0.80(95%CI 0.66-0.99)。
  • 联合组客观缓解率43.7%(95%CI 38.4-49.0)vs 单药组33.7%(95%CI 28.8-38.9)。
  • 大多数预设亚组的疗效倾向于联合治疗。
  • 未发现新的或意料之外的安全性信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nivolumab plus relatlimab demonstrated a statistically significant improvement in progression-free survival (PFS), along with a clinically meaningful, but not statistically significant improvement in overall survival (OS) and a numerically higher objective response rate (ORR) compared with nivolumab in the RELATIVITY-047 trial (ClinicalTrials.gov identifier: NCT03470922). We report updated descriptive efficacy and safety results from RELATIVITY-047 with a median follow-up of 33.8 months. Median PFS was 10.2 months (95% CI, 6.5 to 15.4) with nivolumab plus relatlimab and 4.6 months (95% CI, 3.5 to 6.5) with nivolumab (hazard ratio [HR], 0.79 [95% CI, 0.66 to 0.95]); median OS was 51.0 months (95% CI, 34.0 to not reached) and 34.1 (95% CI, 25.2 to 44.7) months, respectively (HR, 0.80 [95% CI, 0.66 to 0.99]). ORR was 43.7% (95% CI, 38.4 to 49.0) with nivolumab plus relatlimab and 33.7% (95% CI, 28.8 to 38.9) with nivolumab. Efficacy across the majority of prespecified subgroups favored the combination. No new or unexpected safety signals were identified. Overall, at 3-year follow-up, the benefit observed with nivolumab plus relatlimab compared with nivolumab in patients with advanced melanoma was sustained, with the OS HR 95% CI upper bound now <1. This benefit is accompanied by a safety profile consistent with previous reports.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tawbi HA, Hodi FS, Lipson EJ, et al. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. J Clin Oncol. 2024. PMID: 39671533. doi:10.1200/JCO.24.01124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。